Brand Name
Gemtesa
Generic Name
Vibegron
View Brand Information FDA approval date: December 29, 2020
Classification: beta3-Adrenergic Agonist
Form: Tablet
What is Gemtesa (Vibegron)?
GEMTESA is a beta-3 adrenergic agonist indicated for the treatment of: overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
Impact of Early Aging and Menopause on the Vascular Responses to Hypoxia
Summary: The purpose of this study is to examine hypoxic vasodilation and the role of beta-adrenergic receptors in younger premenopausal, perimenopausal, and older postmenopausal women.
A Phase 2/3, Open-label, Baseline-controlled, Multicenter, Long-term Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC)
Summary: The purpose of this study is to evaluate the safety, efficacy, and PK of vibegron in pediatric participants with NDO who are regularly using CIC